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Objectives. This study sought to determine the frequency of
thrombocytopenia and its relation with clinical outcomes in high risk
patients undergoing percutaneous coronary revascularization who
received either the platelet glycoprotein (GP) IIb/IIIa receptor an-
tagonist abciximab (ReoPro, c7E3 Fab) or conventional therapy.
Background. The development of thrombocytopenia on expo-
sure to GPIIb/IIIa antagonists threatens the utility and economic
viability of this drug class for patients with vascular disease.
Methods. We analyzed data from the Evaluation of c7E3 for the
Prevention of Ischemic Complications trial (EPIC), a 2,099-
patient, randomized trial of placebo, abciximab bolus or abcix-
imab bolus plus a 12-h infusion during high-risk coronary revas-
cularization.
Results. Thrombocytopenia (nadir platelet count <100 3 109/
liter) developed in 81 patients (3.9%) during their hospital stay,
with 19 (0.9%) developing severe (<50 3 109/liter) thrombocyto-
penia. Both thrombocytopenia and severe thrombocytopenia were
more frequent in the bolus-plus-infusion arm (5.2% and 1.6%,
respectively) than in the bolus-only and placebo arms combined
(p 5 0.020 and p 5 0.025, respectively). Acute profound throm-
bocytopenia developed in two patients in the bolus-plus-infusion
arm. Patients with thrombocytopenia experienced more unfavor-
able clinical outcomes than those who did not develop thrombo-
cytopenia, regardless of treatment assignment, but those with
thrombocytopenia who received abciximab had fewer worse out-
comes at 30 days. Multivariable logistic modeling revealed a lower
baseline platelet count, older age and lighter weight to be impor-
tant predictors of thrombocytopenia. In a logistic regression
model, bolus-plus-infusion treatment was a significant predictor
of thrombocytopenia (p 5 0.016) and remained so after adjust-
ment for procedures and baseline risk factors (p 5 0.0077).
Conclusions. Thrombocytopenia was associated with adverse
clinical outcomes and excessive bleeding, but patients receiving
abciximab fared better than those receiving placebo.
(J Am Coll Cardiol 1998;32:311–9)
©1998 by the American College of Cardiology
Platelet- and thrombin-mediated thrombosis (1–3) plays a
pivotal role in the development of abrupt closure and acute
ischemic complications after coronary intervention. Pharma-
cologic interruption of this process reduces ischemic events
after coronary intervention, but also leads to a higher risk of
hemorrhagic complications (4–6). Much of the hemorrhagic
risk is attributed to the effect of both thrombin inactivation and
inhibition of platelet function, whereas the contribution of
thrombocytopenia is less well understood. In the setting of the
acute coronary syndromes, trials of thrombolytic therapy pro-
vide the only current source of data on thrombocytopenia.
In the Evaluation of c7E3 for Prevention of Ischemic
Complications (EPIC) trial, the use of a monoclonal chimeric
human-murine antibody Fab fragment to the platelet glyco-
protein (GP) IIb/IIIa receptor (c7E3 Fab, abciximab, ReoPro),
in combination with aspirin and intravenous heparin, produced
a 35% reduction in the 30-day composite-event rate (death,
myocardial infarction or urgent coronary revascularization) in
high risk patients undergoing coronary interventions, as com-
pared with aspirin and heparin therapy alone (5,7). Our
purposes were to define in this study group the frequency of
thrombocytopenia and to analyze its relation to the 30-day
clinical outcomes and hemorrhagic complications.
Methods
Patient group. The inclusion and exclusion criteria, thera-
pies and primary analysis of the EPIC trial have been previ-
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ously published (5). Briefly, 2,099 patients ,80 years of age
undergoing a percutaneous transluminal coronary intervention
(balloon coronary angioplasty or directional coronary atherec-
tomy), with clinical or angiographic attributes associated with a
high risk of abrupt vessel closure, were enrolled.
Patients at risk for bleeding complications (history of
hemorrhagic diathesis, major operation within 6 weeks of
enrollment, gastrointestinal or genitourinary bleeding of clin-
ical significance within the previous 6 weeks, stroke within 2
years of enrollment or any stroke with significant residual
neurologic deficit or presumed or documented history of
vasculitis) were excluded from participation in the study.
All patients received aspirin and intravenous heparin and
were randomly assigned to one of three treatment groups:
placebo bolus plus placebo infusion; abciximab bolus
(0.25 mg/kg body weight) with placebo infusion; or abciximab
bolus (0.25 mg/kg) plus abciximab infusion (10 mg/min). The
bolus was administered within 10 to 60 min before the proce-
dure. The abciximab infusions were given intravenously and
continuously for 12 h unless clinically contraindicated.
Defining the group with thrombocytopenia. Platelet counts
were obtained from complete blood count samples drawn into
EDTA and were determined before the infusion, at 30 min and
at 2, 12 and 24 h after initiation of the study agent, and then
daily until discharge or day 7, whichever occurred first. The
term thrombocytopenia was assigned if there was a nadir
platelet count ,100 3 109/liter and an independent reviewer
excluded pseudothrombocytopenia. The term severe thrombo-
cytopenia was assigned to those nadir platelet counts ,50 3
109/liter. Acute thrombocytopenia was defined as a platelet
count ,100 3 109/liter within 24 h of the initiation of therapy.
Acute severe thrombocytopenia was defined as a platelet count
,50 3 109/liter within 24 h of the initiation of therapy. Acute
profound thrombocytopenia was defined as platelet count
,20 3 109/liter within 24 h of the initiation therapy. Pseudo-
thrombocytopenia was defined as artifactual, in vitro thrombo-
cytopenia detected by automated laboratory cell counters
recognized by preservation of the 30-min platelet count in
citrate anticoagulant, while a simultaneous platelet count in
EDTA anticoagulant was low (,100 3 109/liter). Platelet
clumps were identified on a peripheral blood smear in some
cases, and this was used as an independent criterion for
pseudothrombocytopenia. The protocol recommended that
heparin and aspirin be discontinued if the platelet count
decreased to #60 3 109/liter and that platelet transfusion be
initiated if the platelet count decreased to ,50 3 109/liter.
Bleeding events. Bleeding events were classified as major
or minor according to the Thrombolysis in Myocardial Infarc-
tion trial criteria (8), and net blood loss was computed using
the criteria of Landefeld et al. (9). Details have been described
previously (10).
Statistical analysis. Continuous measures are expressed as
the median values with interquartile ranges (25th and 75th
percentiles), whereas categoric factors are expressed as per-
centages. Multivariable logistic modeling was applied to exam-
ine the relation between baseline patient characteristics and
thrombocytopenia. The effect of abciximab bolus-plus-infusion
treatment on the development of thrombocytopenia was ex-
plored using multiple logistic regression analysis to account for
procedures (coronary artery bypass graft surgery, repeat cath-
eterizations, repeat percutaneous transluminal coronary inter-
vention, balloon pump use, stent implantation) occurring
before the development of thrombocytopenia. A second logis-
tic regression model was developed to examine the effect of
thrombocytopenia on a “major bleeding” outcome after ad-
justment for previously identified predictors of bleeding (10).
Multiple linear regression techniques were used in parallel to
explore the relation between thrombocytopenia and the bleed-
ing index in the presence of known predictors. All clinical
outcomes reported are at 30 days.
Results
Thrombocytopenia. True thrombocytopenia developed in
81 (3.9%) of the 2,099 patients undergoing high-risk percuta-
neous coronary revascularization, with 19 (0.9%) developing
severe thrombocytopenia at some point during the index
hospital period (Table 1). Pseudothrombocytopenia was as-
signed by a masked reviewer (D.C.S.) to 8 patients (1.1%) in
the bolus-plus-infusion arm, 18 patients (2.6%) in the bolus-
only arm and 9 patients (1.3%) in the placebo arm. Both
thrombocytopenia and severe thrombocytopenia were more
frequent among patients treated with bolus plus infusion (p 5
0.020 and p 5 0.025, respectively) than among patients receiv-
ing bolus only or placebo. The absolute platelet decline
(baseline platelet count minus nadir platelet count) was
greater for all patients in the bolus-plus-infusion group than
for all patients in the placebo group (Wilcoxon rank-sum test,
p 5 0.019). The median time to the development of thrombo-
cytopenia tended to be shorter in patients receiving abciximab
(0.50 vs. 1.68 days). There was no difference observed in the
duration of thrombocytopenia between treatments.
Acute thrombocytopenia. Acute thrombocytopenia, acute
severe thrombocytopenia and acute profound thrombocytope-
nia occurred more frequently among patients treated with
bolus plus infusion than among patients receiving placebo (p 5
0.002 for acute thrombocytopenia) (Table 1). Two cases of
acute profound thrombocytopenia occurred in this trial. Both
were in the bolus-plus-infusion treatment group. Patient 1 had
a baseline platelet count of 205 3 109/liter. Two hours after the
abciximab bolus a nadir count of 2 3 109/liter was discovered.
Twelve units of platelets raised the count to 13 3 10/liters and
Abbreviations and Acronyms
EPIC 5 Evaluation of c7E3 for the Prevention of Ischemic
Complications trial
GP 5 glycoprotein
HACA 5 human anti-chimeric antibody
LIBS 5 ligand-induced binding site
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another 12 U raised it to 77 3 109/liter. No bleeding occurred.
Two weeks later the count was 409 3 109/liter. Patient 2 had a
baseline platelet count of 147 3 109/liter. Two hours after the
bolus the count was 19 3 109/liter (performed in citrate). The
patient twice received 10 U of platelets and was begun on
intravenous immunoglobulin and steroids. The patient’s count
then rose to 103 3 109/liter 3.5 days after receiving abciximab.
No bleeding occurred.
Baseline characteristics associated with thrombocytopenia.
The distributions of the key baseline characteristics for pa-
tients who developed thrombocytopenia are displayed in Table
2. Univariably, thrombocytopenia occurred more often in
patients who were older, of lighter weight, of African ancestry
and had peripheral vascular disease or three-vessel coronary
artery disease.
Unfavorable outcomes associated with thrombocytopenia.
Patients with thrombocytopenia more commonly experienced
unfavorable clinical outcomes (death, myocardial infarction,
bypass surgery, additional percutaneous revascularization and
balloon pump insertion) and longer median lengths of stay in
the coronary care unit and hospital than those who did not
develop thrombocytopenia, regardless of treatment assignment
(Table 3). Patients who developed thrombocytopenia had
significantly fewer undesirable outcomes (excluding death and
additional percutaneous transluminal coronary intervention) if
they were treated with abciximab (bolus only or bolus 1
Table 1. Thrombocytopenia in the Hospital and Within 24 H by Treatment Assignment
Bolus 1 Infusion
(n 5 708)
Bolus
(n 5 695)
Placebo
(n 5 696)
All Patients
(n 5 2,099)
p
Value*
p
Value†
In the hospital
Thrombocytopenia‡ (nadir ,100 3 109/liter) 5.2% (3.6–6.8) 3.0% (1.7–4.3) 3.3% (2.0–4.6) 3.9% (3.1–4.7) , 0.075 0.020
(n 5 37) (n 5 21) (n 5 23) (n 5 81)
Absolute platelet decline§ (3109/liter) 135 (77–166) 130 (80–143) 149 (63–175) 136 (72–167) , 0.019
Duration of thrombocytopenia (days) 2.22 (1–3.33) 2.10 (0.47–3.02) 2.04 (1.43–3.45) 2.11 (1–3.35)
Time to thrombocytopenia (days) 0.50 (0.03–3.04) 1.03 (0.11–3.65) 1.68 (0.53–2.53) 0.99 (0.08–3.04) 0.100
Platelet decline .50% from baseline 6.5% (4.7–8.3) 4.3% (2.8–5.8) 3.9% (2.5–5.3) 4.9% (4.0–5.8) 0.027 0.016
(n 5 46) (n 5 30) (n 5 27) (n 5 103)
Severe thrombocytopenia‡ (nadir ,50 3 109/liter) 1.6% (0.7–2.5) 0.4% (0–0.87) 0.7% (0.08–1.32) 0.9% (0.50–1.30) , 0.140 0.025
(n 5 11) (n 5 3) (n 5 5) (n 5 19)
Absolute platelet decline§: all patients (3109/liter) 35 (14–69) 34 (14–66) 31 (15–55) 33 (14–62)
Within 24 h
Acute thrombocytopenia\ (count ,100 3 109/liter) 2.7% (1.5–3.9) 1.2% (0.4–2.0) 0.6% (0.03–1.2) 1.5% (1.0–2.0) 0.002
(n 5 19) (n 5 8) (n 5 4) (n 5 31)
Acute severe thrombocytopenia\ (count ,50 3 109/liter) 0.8% (0.1–1.5) 0.1% (0–0.3) 0 0.3% (0.1–0.5)
(n 5 6) (n 5 1) (n 5 7)
Acute profound thrombocytopenia (count ,20 3 109/liter) 0.3% (0–0.7) 0 0 0.1% (0–0.2)
(n 5 2) (n 5 2)
*Bolus plus infusion versus placebo group. †Bolus plus infusion versus bolus and placebo groups. ‡Determined after an independent reviewer excluded
pseudothrombocytopenia. §Absolute platelet decline 5 (baseline platelet count 2 nadir platelet count) 3 109/liter. Thrombocytopenia values are presented as median
percentages (95% confidence interval) of patients in the category. Absolute platelet decline, duration of thrombocytopenia and time to thrombocytopenia data are
presented as median values (25th to 75th percentiles). \Includes patients with acute severe or acute profound thrombocytopenia.
Table 2. Relation of Clinical Characteristics With Thrombocytopenia* by Treatment Assignment
Any Abciximab Bolus 1 Infusion Placebo All Patients
T
(n 5 58)
No T
(n 5 1,345)
T
(n 5 37)
No T
(n 5 671)
T
(n 5 23)
No T
(n 5 673)
T
(n 5 81)
No T
(n 5 2,018)
Age, years (median, Q1–Q3) 67 (56–73) 61 (52–68) 65 (55–71) 62 (52–68) 67 (57–72) 61 (53–68) 67 (57–73) 61 (52–68)
Weight, kg (median, Q1–Q3) 78 (68–86) 83 (73–93) 80 (73–87) 84 (73–93) 80 (74–91) 85 (74–95) 79 (70–87) 84 (73–94)
Male gender 75.9% (44) 71.7% (964) 71.1% (26) 70.3% (480) 60.9% (14) 73.1% (492) 71.6% (58) 72.2% (1,456)
Race
Caucasian 87.9% (51) 91.9% (1,236) 91.9% (34) 92.0% (617) 100% (23) 92.6% (623) 91.4% (74) 92.1% (1,859)
African ancestry 10.3% (6) 4.9% (66) 8.1% (3) 5.4% (36) 0% 4.0% (27) 7.4% (6) 4.6% (93)
Hypertension 53.5% (31) 54.3% (726) 46.0% (17) 54.0% (361) 65.2% (15) 54.1% (363) 56.8% (46) 54.2% (1,089)
Diabetes mellitus 15.5% (9) 23.5% (316) 18.9% (7) 23.3% (156) 34.8% (8) 25.6% (172) 21.0% (17) 24.2% (488)
Peripheral vascular disease 15.8% (9) 8.6% (115) 13.9% (5) 8.9% (59) 13.0% (3) 8.4% (56) 15.0% (12) 8.5% (171)
Cerebrovascular disease 5.2% (3) 3.9% (53) 8.1% (3) 4.2% (28) 0% 3.4% (23) 3.7% (3) 3.8% (76)
Three-vessel coronary artery disease 24.1% (14) 13.5% (181) 21.6% (8) 12.6% (84) 30.4% (7) 15.8% (106) 25.9% (21) 14.2% (287)
*Defined as a nadir platelet count ,100 3 109/liter after an independent reviewer excluded pseudothrombocytopenia. Data are presented as percentage (number)
or median value (25th to 75th percentiles) of patients in the category. Abciximab 5 Bolus only plus Bolus 1 Infusion groups. T 5 thrombocytopenia.
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infusion) versus placebo. A definitive causal relation between
thrombocytopenia and worse clinical outcomes and could not
be determined. The outcome events of myocardial infarction,
percutaneous coronary revascularization and bypass grafting
occurred before the development of thrombocytopenia in 75%
to 80% of the patients with thrombocytopenia. The possibility
that early discontinuation of the study medication for acute
thrombocytopenia led to the development of an unfavorable
clinical outcome did not appear to be the case: only five
patients developed both thrombocytopenia and an undesirable
clinical event before completion of the study medication
infusion.
Hemorrhage associated with thrombocytopenia. The he-
matologic variables associated with the development of throm-
bocytopenia are shown in Table 4. Less hemorrhage, as judged
by the bleeding index, occurred in patients with thrombocyto-
penia who were treated with abciximab as compared with
placebo (p 5 0.046), and they required fewer packed red cell
transfusion (p 5 0.018).
Bleeding events associated with thrombocytopenia are pre-
sented in Table 5. Among patients who received placebo,
major bleeding was more common (69.6% vs. 4.5%) in those
with thrombocytopenia than in those with normal platelet
counts. Among patients who received abciximab, major bleed-
Table 3. Relation of Clinical Outcomes at 30 Days With Thrombocytopenia* by Treatment Assignment
Any Abciximab Bolus 1 Infusion Placebo All Patients
T
(n 5 58)
No T
(n 5 1,345)
T
(n 5 37)
No T
(n 5 671)
T
(n 5 23)
No T
(n 5 673)
T
(n 5 81)
No T
(n 5 2,018)
Mortality 12.1% (7)† 1.0% (14) 10.8% (4) 1.2% (8) 13.0% (3) 1.3% (9) 12.4% (10) 1.1% (23)
Myocardial infarction 20.7% (12)‡ 5.1% (68) 21.6% (8) 4.3% (29) 65.2% (15) 6.7% (45) 33.3% (27) 5.6% (113)
CABG 22.4% (13)§ 3.7% (50) 24.3% (9) 3.9% (26) 60.9% (14) 3.6% (24) 33.3% (27) 3.7% (74)
Additional PTCR 6.9% (4)\ 5.5% (74) 0% 5.1% (34) 21.7% (5) 8.9% (60) 11.1% (9) 6.6% (134)
Balloon pump insertion 13.8% (8)¶ 2.4% (32) 13.5% (5) 2.7% (18) 47.8% (11) 1.8% (12) 23.5% (19) 2.2% (44)
Stent placement 1.7% (1) 1.2% (16) 2.7% (1) 0.5% (3) 0% (0) 0.6% (4) 1.2% (1) 1.0% (20)
Composite end point# 48.3% (28) 14.3% (182) 46.0% (17) 13.4% (90) 82.6% (19) 17.8% (120) 58.0% (47) 15.5% (312)
Length of initial CCU stay (days) 3 (1–7) 1 (0–3) 2 (1–6) 1 (0–3) 3 (1–4) 1 (0–3) 3 (1–7) 1 (0–3)
Length of initial hospital stay (days) 5 (3–12) 3 (2–4) 4 (3–12) 3 (2–5) 8 (4–15) 3 (2–4) 7 (3–12) 3 (2–4)
*Defined as a nadir platelet count ,100 3 109/liter after an independent reviewer excluded pseudothrombocytopenia. †p 5 0.904 versus thrombocytopenia in
placebo group. ‡p , 0.0001 versus thrombocytopenia in placebo group. §p , 0.001 versus thrombocytopenia in placebo group. \p , 0.069 versus thrombocytopenia
in placebo group. ¶p 5 0.002 versus thrombocytopenia in placebo group. #Composite end point 5 death, nonfatal myocardial infarction, any coronary artery bypass
graft surgery, any percutaneous transluminal coronary revascularization, balloon pump insertion and stent placement. Data are presented as percentage (number) or
median value (25th to 75th percentiles) of patients in the category. Any Abciximab 5 Bolus only plus Bolus 1 Infusion groups; CABG 5 coronary artery bypass grafting;
CCU 5 cardiac care unit; PTCR 5 percutaneous transluminal coronary revascularization; T 5 thrombocytopenia.
Table 4. In-Hospital Hematologic Variables Observed With Thrombocytopenia* by Treatment Assignment
Any Abciximab Bolus 1 Infusion Placebo All Patients
T
(n 5 58)
No T
(n 5 1,345)
T
(n 5 37)
No T
(n 5 671)
T
(n 5 23)
No T
(n 5 673)
T
(n 5 81)
No T
(n 5 2,018)
Nadir platelet count 3 109/liter 77 (50–92) 196 (160–238) 75 (33–92) 197 (163–235) 72 (51–91) 198 (164–242) 75 (51–92) 197 (161–239)
Absolute decrease† 3 109/liter 133 (79–164) 33 (13–62) 135 (77–166) 33 (13–64) 149 (63–175) 30 (14–53) 136 (72–167) 32 (14–59)
Relative decrease (%) 63 (48–82) 14 (6–25) 62 (48–83) 14 (6–25) 71 (40–78) 13 (6–21) 63 (46–81) 14 (6–23)
Baseline hematocrit (%) 39 (37–43) 41 (38–44) 40 (37–43) 41 (37–44) 42 (39–45) 41 (38–44) 40 (38–43) 41 (38–44)
Nadir hematocrit (%) 27 (22–35) 34 (29–37) 28 (23–32) 33 (29–37) 25 (22–29) 35 (32–38) 26 (22–32) 34 (30–38)
Absolute change, HCT (%) 13 (6–17) 7 (4–10) 13 (7–17) 7 (4–10) 18 (12–23) 5 (3–8) 14 (7–18) 6 (4–9)
Transfusions
Packed red cells‡ 44.8% (26) 13.0% (175) 37.8% (14) 14.2% (95) 73.9% (17) 4.8% (32) 53.1% (43) 10.3% (207)
.2 U red cells received for
all patients
39.7% (23) 5.5% (74) 32.4% (12) 6.1% (41) 47.8% (11) 1.8% (12) 42.0% (34) 4.3% (86)
Platelets§ 36.2% (21) 3.5% (47) 37.8% (14) 3.7% (25) 47.8% (11) 1.0% (7) 39.5% (32) 2.7% (54)
Bleeding index
All patients\ 4.8 (2–10.9) 2.2 (1.4–3.5) 4.4 (2.5–10.9) 2.3 (1.4–3.6) 8.7 (6.3–13.2) 1.8 (1.1–2.6) 6.5 (2.6–11.4) 2.0 (1.3–3.1)
Nonsurgical patients 3.8 (1.7–9.2) 2.2 (1.3–3.3) 3.6 (1.9–5.6) 2.2 (1.3–3.4) 8.0 (2.3–11.7) 1.7 (1.1–2.5) 4.0 (1.8–9.4) 2.0 (1.3–3)
*Defined as a nadir platelet count ,100 3 109/liter after an independent reviewer excluded pseudothrombocytopenia. †Baseline platelet count minus nadir platelet
count (absolute platelet decline). ‡p 5 0.018 (any abciximab vs. placebo). §p 5 0.335 (any abciximab vs. placebo). \p 5 0.046 (any abciximab vs. placebo). Data are
presented are percentage (number) or median values with interquartile range (25th to 75th percentiles) of patients in the category. Any Abciximab 5 Bolus only plus
Bolus 1 Infusion groups; T 5 thrombocytopenia.
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ing was again more common in those with thrombocytopenia
than in those without it (43.1% vs. 11.2%). Among patients
with thrombocytopenia, major bleeding was more common if
they received placebo instead of abciximab (69.6% vs. 43.1%,
p 5 0.030). Intracranial hemorrhage was not clinically appar-
ent in patients with thrombocytopenia who received abciximab.
Predictors of developing thrombocytopenia. Multivariable
logistic modeling, applied to examine the relation between
selected baseline patient characteristics and thrombocytope-
nia, revealed three important predictors of developing throm-
bocytopenia: lower baseline platelet count, older age and
lighter weight (Table 6A). The probability of developing
thrombocytopenia over the observed range of baseline platelet
count, age and weight is shown in Figure 1. A risk score
developed to show the overall incidence of thrombocytopenia
according to the number of baseline risk factors present
highlights the importance of these predictors; if a patient .65
years old, weighing ,80 kg, presented with a baseline platelet
count ,200 3 109/liter, the patient’s risk of developing throm-
bocytopenia in the hospital was nearly 10% (Table 6B).
Although patients with advancing age and lower body weight
were previously shown in the EPIC trial to be at higher risk of
postprocedural ischemic events, no correlation was found
between the number of risk factors present for developing
thrombocytopenia and the rate of adverse events.
Effect of abciximab on development of thrombocytopenia.
The effect of abciximab bolus-plus-infusion treatment on the
development of thrombocytopenia was explored using multiple
logistic regression analysis to account for procedures per-
formed before the occurrence of thrombocytopenia. These
procedures included cardiac catheterization, percutaneous
transluminal coronary revascularization, stent or balloon pump
placement and bypass surgery. Without adjustment for proce-
dures and baseline risk factors (initial platelet count, age and
weight), abciximab bolus plus infusion proved to be an impor-
tant predictor of thrombocytopenia (chi-square statistic 5.8,
p 5 0.016). After adjusting for the predictive effect of the
procedures and the presence of baseline risk factors (chi-
square 172.5, p , 0.0001), the bolus-plus-infusion treatment
remained a significant predictor of thrombocytopenia (chi-
square 7.1, p 5 0.0077).
Role of thrombocytopenia in major bleeding. Predictors of
bleeding in the EPIC population were previously identified
(10). In the current analysis, a logistic regression model was
developed to examine the effect of thrombocytopenia on the
“major bleeding” outcome after adjustment for these predic-
tors of bleeding (chi-square 300.51, p , 0.0001), and it
validated thrombocytopenia as a significant additional predic-
tor of major bleeding (chi-square 13.04, p 5 0.0003). Multiple
linear regression techniques used in parallel to explore the
relation between thrombocytopenia and the bleeding index in
the presence of known predictors proved thrombocytopenia to
Table 5. Relation of Bleeding Events at 30 Days With Thrombocytopenia* by Treatment Assignment
Total patients
(n 5 2,099)
Any Abciximab Bolus 1 Infusion Placebo All Patients
T
(n 5 58)
No T
(n 5 1,345)
T
(n 5 37)
No T
(n 5 671)
T
(n 5 23)
No T
(n 5 673)
T
(n 5 81)
No T
(n 5 2,018)
Major bleeding
(n 5 222)
43.1% (25) 11.2% (151) 40.5% (15) 12.5% (84) 69.6% (16) 4.5% (30) 50.6% (41) 9.0% (181)
[23.7–62.5] [6.2–16.2] [15.7–65.3] [5.4–19.6] [47.1–92.1] [0–11.9] [35.3–65.9] [4.8–13.2]
Intracranial hemorrhage
(n 5 6)
0 0.3% (4) 0 0.5% (3) 0 0.3% (2) 0 0.3% (6)
[0–5.7] [0–8.5] [0–7.9] [0–4.7]
Groin (n 5 963) 67.2% (39) 53.7% (722) 62.2% (23) 54.6% (366) 39.1% (9) 28.7% (193) 59.3 (48) 45.3% (915)
[52.5–81.9] [50.1–57.3] [42.4–82.0] [49.5–59.7] [7.2–71.0] [22.3–35.1] [45.4–73.2] [42.1–48.5]
Retroperitoneal (n 5 23) 6.9% (4) 1.2% (16) 8.1% (3) 1.8% (12) 8.7% (2) 0.2% (1) 7.4% (6) 0.8% (17)
[0–31.7] [0–6.5] [0–39.0] [0–9.3] [0–47.8] [0–9.0] [0–28.3] [0–5.0]
*Defined as a nadir platelet count ,100 3 109/liter after an independent reviewer excluded pseudothrombocytopenia. Data are presented as percentage (number)
of patients with or without thrombocytopenia who had a bleeding event [95% confidence intervals]. Any Abciximab 5 Bolus only plus Bolus 1 Infusion groups; T 5
thrombocytopenia.
Table 6. Prediction and Overall Incidence of Thrombocytopenia
A. Prediction of Thrombocytopenia Using Baseline Characteristics*
Coefficient
Chi-
Square† p Value
Baseline platelet count 20.016 49.92 , 0.0001
Age (years) 0.049 8.20 0.0042
Weight (kg) 20.023 7.81 0.0052
*Baseline platelet count truncated above 320 3 109/liters; age truncated
below 58 years. †Concordance index 5 0.76, model chi-square 5 73.55.
B. Risk Score: Overall Incidence of Thrombocytopenia According
to Number of Baseline Risk Factors Present
Number of
Risk Factors*
Incidence of Thrombocytopenia
(,100 3 109/liter)
0 1.8%
1 2.3%
2 8.0%
3 9.8%
*Risk score is calculated as follows: A value of 1 is assigned to each of the
risk factors predictive of the development of thrombocytopenia, within certain
variables (baseline platelet count ,200 3 109/liter, age .65 years and weight
,80 kg). A risk score is calculated by adding the assigned score. The maximal
possible risk score is 3.
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Figure 1. The probability (with 95% confidence
intervals) of developing thrombocytopenia over the
observed range of baseline platelet count (A), age
(B) and weight (C).
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be a very potent predictor of an increased bleeding index
(chi-square 114.98, p , 0.0001).
Discussion
Thrombocytopenia is an important and not infrequent
occurrence in patients with medically intractable unstable or
postinfarction angina undergoing revascularization without
thrombolytic therapy. In the EPIC trial, thrombocytopenia was
associated with undesirable ischemia-related outcomes, includ-
ing death, and excessive hemorrhage. Important predictors
were a lower baseline platelet count, older age and lighter
weight. We noted an increased likelihood of thrombocytopenia
in patients receiving abciximab, particularly as a bolus plus
infusion. However, patients who developed thrombocytopenia
but who also had received abciximab had fewer worse out-
comes (re-infarction, need for intraaortic balloon pump or
bypass surgery).
Thrombocytopenia is associated with excessive bleeding.
Thrombocytopenia in the EPIC trial, regardless of whether the
patient was treated with abciximab or not, was also a significant
additional predictor of major bleeding and a very potent
predictor of an increased bleeding index. Among the 2,018
patients who did not develop thrombocytopenia, more bleeding
events were recorded in those who received abciximab than in
those who received placebo, as would be expected with antag-
onism of the platelet GPIIb/IIIa receptor. Among the 81
patients who developed thrombocytopenia, treatment with
abciximab was associated with less bleeding as compared with
thrombocytopenia without abciximab; these patients endured
fewer major bleeding events and fewer transfusions of packed
red blood cells than those who received placebo. This appears
counter-intuitive in light of the published report of the bleed-
ing complications in the entire EPIC population (10). How-
ever, that study did not separately analyze patients to evaluate
the effect of thrombocytopenia and focused on major bleeding
unrelated to bypass surgery. Owing to the small number of
patients with thrombocytopenia (81 of 2,099), the effect of
thrombocytopenia on bleeding within each treatment group
may have been diluted in that analysis.
Thrombocytopenia associated with abciximab infusion is
distinct. A distinct subgroup of patients with thrombocytope-
nia who had received abciximab was observed. Patients with
thrombocytopenia who received placebo were a sicker group:
they had worse clinical outcomes, had a higher bleeding index
(p 5 0.0462) and were more frequently transfused with packed
red blood cells (p 5 0.018). They developed thrombocytopenia
later; 24 h after initiation of treatment the frequency of
thrombocytopenia among patients in the placebo group was
half that of those who received abciximab (Fig. 2). In the
abciximab-treated group the observed frequency of thrombo-
cytopenia was higher, but it was quantitatively less severe.
Acute thrombocytopenia in the EPIC trial. Acute throm-
bocytopenia was observed almost exclusively in abciximab-
treated patients. The two patients who developed acute pro-
found thrombocytopenia had received abciximab. Although
rare, the entity of acute profound thrombocytopenia associated
with abciximab has been described, and the evaluation and
management has been reviewed (11,12). These two patients
had platelet counts detected below 20 3 109/liter at the 2-h
platelet count evaluation. This was found in previously re-
ported cases and supports the package insert recommendation
to obtain a platelet count at 2 to 4 h after abciximab initiation.
Analysis of the time to thrombocytopenia revealed that one-
third of patients had thrombocytopenia 2 h after the abciximab
bolus and one-half of them had it 12 h after. Although it cannot
be determined at that stage which cases of thrombocytopenia
are related to abciximab therapy, evaluation of the platelet
count soon after initiation of abciximab identifies the patients
at risk, potentially permitting sufficient time to discontinue the
infusion with effect. In the initial reports of profound throm-
bocytopenia (11–13), platelet transfusion was efficacious and
Figure 2. Cumulative distribution function plot depict-
ing the cumulative development of thrombocytopenia
over time in patients receiving abciximab as compared
with those receiving placebo.
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was not associated with worsening thrombocytopenia or
thrombosis. Transfusion is recommended if the platelet count
is below 20 3 109/liter.
Potential mechanisms for abciximab-associated thrombo-
cytopenia. The mechanism of the thrombocytopenia observed
with abciximab infusion is not understood, although postulates
exist. Antibodies to the GPIIb/IIIa receptor can be encoun-
tered in immune and drug-induced thrombocytopenias (14,15),
but by design abciximab has no Fc portion, making untenable
the hypothesis that platelets with abciximab on their GPIIb/
IIIa receptors are removed from the circulation by the Fc
receptors of the macrophages of the reticuloendothelial sys-
tem. This does not, however, rule out the development of
aggregates of platelets and c7E3 Fab and subsequent removal
from the circulation. Another consideration is the potential
presence of residual uncleaved c7E3 Fab2 in the infused
preparation, but this appears unlikely according to data from
the manufacturer (personal communication of Robert Jordan,
Centocor). Because the construction of the abciximab frag-
ment requires cleavage of the chimeric antibody across the
hinge region of the molecule, a human anti-chimeric antibody
(HACA) reaction to this damaged human antibody structure
might occur after abciximab infusion. The development of a
HACA response suggests that the potential for immune-
mediated reactions exists. In the EPIC trial, the development
of HACA within the first 12 weeks of exposure to abciximab
was 5.8% overall, with 6.5% developing in the bolus-plus-
infusion group, 5.2% in the bolus-only group and none in the
placebo group (16). Also detected was a low affinity pre-
immune (pre-dose) HACA reactivity in 8% of the patients in
EPIC, which appeared to be specific for the Fab cleavage site
of human immunoglobulins. However, no correlation was
observed between pre-dose or induced HACA and thrombo-
cytopenia (personal communication of Carrie L. Wagner,
Centocor).
Binding of abciximab to the GPIIb/IIIa receptor could
conceivably produce a conformational change, resulting in the
expression of new epitopes, termed ligand-induced binding
sites (LIBS) (17). If patients have preformed antibodies that
cross react with LIBS, the platelets may become coated with
immunoglobulin and be removed from the circulation. Bednar
et al. (18) reported the presence in human plasma samples of
preexisting immunoglobulin G–type antibodies that selectively
bound to platelets in the presence of their GPIIb/IIIa antago-
nist and led to thrombocytopenia.
Platelet modifications might also be created either by the
presence of abciximab on the platelet surface in relation to
other platelet antigens or by the ability of abciximab to bind to
the vitronectin (avb3) receptor (where it can inhibit platelet-
mediated thrombin generation) or the Mac-1 (CD11b/CD18)
integrin receptors of activated monocytes (19). The unusual
pharmacokinetic properties of the abciximab bolus plus infu-
sion (13,20,21) might heighten the opportunity for the evolu-
tion of these scenarios; there is an extended platelet-bound
half-life, with small amounts of the drug remaining on circu-
lating platelets for 15 days or more (16). Any of the these
aforementioned developments could culminate in platelet ac-
tivation and platelet–platelet interactions with consumption or
removal of the platelets from the circulation by macrophages
of the reticuloendothelial system.
Study limitations. This analysis has certain limitations. A
definitive delineation of the cause(s) for each of the 81 cases of
thrombocytopenia was not possible. The thrombocytopenia
protocol was primarily designed to detect the presence of
pseudothrombocytopenia and HACA-induced thrombocyto-
penia; poor compliance with other aspects of the workup of
thrombocytopenia led to incomplete investigation of other
potential causes. Clean data are not available to evaluate the
presence of heparin-induced thrombocytopenia. Data on hep-
arin use were only obtained in the catheterization laboratory;
once the patient left the laboratory, only the highest and lowest
rates of heparin infused during the first 3 days were collected.
Plasma samples to detect antibodies to heparin were collected
in the extreme minority of cases. Also, the relation between
thrombocytopenia and procedure could not be defined be-
cause only the day, and not the time, of the procedures was
collected. Still, our analysis represents an important descrip-
tion of thrombocytopenia and augments the limited knowledge
developed from previous studies of thrombocytopenia in the
setting of acute coronary syndromes, most of which were
derived from patients treated with thrombolytic therapy
(8,22,23)
Conclusions. Thrombocytopenia was a frequent covariate
among patients who developed ischemia-associated morbidity
and mortality; however, among patients with thrombocytope-
nia, treatment with abciximab was associated with fewer isch-
emic events and less bleeding. Independent predictors of
thrombocytopenia were lower baseline platelet count, in-
creased age, lighter weight and treatment with bolus plus
infusion of abciximab. The subgroup with thrombocytopenia
with abciximab treatment appeared to be distinct from other
types of thrombocytopenia and could be detected by a declin-
ing platelet count in the first 24 h after therapy initiation. A
platelet count performed at 2 to 4 h after the abciximab
infusion is begun will identify those patients at risk of devel-
oping thrombocytopenia, especially those who will develop
acute severe and acute profound thrombocytopenia.
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